HK Stock Market Move | CAMBRIDGE-B (01228) surges over 12% after earnings, company turns loss into profit in the first half of the year, recently reached a strategic cooperation with Qingdao Baheal Medical INC.

CANBRIDGE-B (01228) rose more than 12% after the performance report, closing at 9.48% higher, at 2.54 Hong Kong dollars, with a turnover of 1031.41 million Hong Kong dollars. On the news front, Beihai Kangcheng released its interim performance, with revenue of 22.248 million yuan in the first half of the year, a decrease of 50.33% year-on-year; net profit was 59.238 million yuan, compared to a loss of 247 million yuan in the same period last year, achieving a turnaround from loss to profit. The announcement stated that the decrease in revenue was mainly due to the company's original plan to strategically focus on rare diseases in 2021, and sales of HeLiAn in Taiwan stopped after the distribution agreement with HeLiAn was terminated at the end of 2024. In addition to the sales of HeLiAn in Taiwan, the company's revenue decreased by 1.7 million yuan or 6.9% compared to the same period in 2024, mainly due to Beihai Kangcheng's active inventory management in the first half of 2025 and reducing inventory in the distribution channel. It is worth noting that in August 2025, Beihai Kangcheng announced the signing of a share subscription agreement with Qingdao Baheal Medical INC., under which Qingdao Baheal Medical INC. will subscribe for Beihai Kangcheng shares for 100 million Hong Kong dollars. At the same time, Beihai Kangcheng and Qingdao Baheal Medical INC. further deepened their strategic cooperation by signing an exclusive commercial service agreement. According to the agreement, a subsidiary of Qingdao Baheal Medical INC. will have the right to promote specific products under Beihai Kangcheng in mainland China, Hong Kong, and Macau.